Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

CrystalGenomics (Korea) a clinical-stage biopharmaceutical company focused on chemoproteomics based drug discovery company working on an NSAID, antibiotics for MRSA and HIF inhibitors for hypoxia, therapeutics for cancer, closed a third tranche of $2.6M Series A financing bringing the total round to $20M. Participants include Korea Seoul Life Sciences Fund, Hanwha Venture Capital and Oxford […]

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $12M Series C financing. Participants were not identified.

Affinium Pharmaceuticals (Austin, TX) a clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections, closed a $15M Series B financing. Participants include SV Life Sciences, Genesis Capital Partners, Forward Ventures and Ontario Emerging Technologies Fund. Thanx for your patience as we catch-up.

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $10.5M Series B financing. Participants were not identified.

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $20M Series E financing. Participants have included Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $4.5M Series A financing. Participants were not identified.

Molecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.

Nabriva Therapeutics (Austria) a clinical-stage based developer of antibiotics for treating multi-drug resistant pathogens, closed a $22M Series B financing. Participants include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures and Novartis Venture Fund. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Molecular Detection (Wayne, PA) a development-stage molecular diagnostics company focused on reat-time PCR of MRSA detection, closed a $3.3M Series C financing. Participants include MentorTech Ventures, Ben Franklin Technology Partners, Robin Hood Ventures and the Mid-Atlantic Angel Group.

AdvanDx (Woburn, MA) a commercial-stage molecular diagnostics company focused on MRSA, Stap aureus and enterococci assays, closed a $8M Series C financing. Participants include SLS Venture and LD Pensions.

Concert Pharmaceuticals (Lexington, MA) development-stage pharmaceutical company focused on new chemical entities based upon modifications of validated drug molecules using deuterium chemistry, closed a $37M Series C financing. Participants include Adage Capital Management, SR One, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund, Flagship Ventures, Greylock […]

Adnavance (Canada) developer of DNA detection molecular diagnostic tests for MRSA identification closed a $3.7M Series B financing. Participants include GrowthWorks Capital, JovInvestment Management and Business Development Bank of Canada.

  

to top of page...